This listing of claims will replace all prior versions and listing of claims in the application.

Claims 1-22 (canceled)

23. (Currently amended) The compound of ~~Claim 22~~ Claim 41 wherein R^1 is hydrogen, C_{1-4}alkyl, C_{1-4}alkoxy, halogen or CF_3.

24. (Currently amended) The compound of ~~Claim 22~~ Claim 41 wherein R^2 is hydrogen, C_{1-4}alkyl, C_{1-4}alkoxy, halogen or CF_3.

25. (Currently amended) The compound of ~~Claim 22~~ Claim 41 wherein R^3 is hydrogen, fluorine, chlorine or CF_3.

26. (Currently amended) The compound of ~~Claim 22~~ Claim 41 wherein R^4 is hydrogen or fluorine.

27. (Currently amended) The compound of ~~Claim 22~~ Claim 41 wherein R^5 is hydrogen, fluorine, chlorine or CF_3.

28. (Currently amended) The compound of ~~Claim 22~~ Claim 41 wherein R^6 is C_{1-4}alkyl optionally substituted by hydroxy.

29. (Currently amended) The compound of ~~Claim 22~~ Claim 41 wherein R^7 is a cyclic group selected from the group consisting of:



X is N, CH or CH_2 ,



X is O or CH_2
n is 1 or 2 ,



X is O, NH, CH_2 or NR^{13}
n is 1 or 2 ,



X is NH or CH_2 ,



X is O, NH, CH_2 or NR^{13}
n is 1 or 2 ,



X is O, NH, CH_2 or NR^{13}
n is 1 or 2 ,



,



,



,



,



,



X is NR^{13} or CH_2 ,



X is NR^{13} or CH_2 ,



,


,


,

X is NR^{13} or CH_2

X is NR^{13}, O or SO_2



,


,


,

X is N or CH

X is N or CH



and


,

X is N or CH

wherein any of said cyclic groups is unsubstituted or substituted by one or more groups as defined in ~~Claim 22~~ Claim 41.

30. (Currently amended) The compound of ~~Claim 22~~ Claim 41 wherein R^7 is a cyclic group selected from the group consisting of:



,


and


,

whereinany of said cyclic groups is unsubstituted or substituted by one or more groups as defined in ~~Claim 1~~ Claim 41.

31. (Currently amended) The compound of ~~Claim 22~~ Claim 41 wherein R^8 is hydrogen or methyl.

32. (Currently amended) The compound of ~~Claim 22~~ Claim 41 wherein R^{12} is hydrogen, hydroxy, C_{1-2}alkyl substituted by hydroxy, C_{1-4}alkoxy or CO_2R^e, where R^e is hydrogen, methyl ethyl or benzyl.

33. (Currently amended) The compound of ~~Claim to 11~~ Claim 41wherein R^{13} represents hydrogen, methyl or ethyl.

34. (Currently amended) The compound of ~~Claim 22~~ Claim 41 wherein R^{15} is hydrogen and R^{16} is hydrogen.

35. (Currently amended) The compound of ~~Claim 22~~ Claim 41 wherein n is zero or 1.

36. (Currently amended). The compound of ~~Claim 22~~ Claim 41 of the formula (Ia):



(Ia)

wherein:

A^1 is fluorine or CF_3;

A^2 is fluorine or CF_3;

A^3 is fluorine or hydrogen;

A^4 is fluorine or hydrogen;

A^5 is methyl;

or a pharmaceutically acceptable salt thereof.

37. (Previously added) A compound which is selected from the group consisting of:
1-[((2*R*,3*R*,4*R*)-2-{(1*R*)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy}-tetrahydro-3-(4-fluorophenyl)-2*H*-pyran-4-yl)methyl]piperazinone;
1-[((2*R*,3*R*,4*R*)-2-{(1*R*)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy}-tetrahydro-3-(4-fluorophenyl)-2*H*-pyran-4-yl)methyl]-4-methylpiperazinone;
1-[((2*R*,3*R*,4*R*)-2-{(1*R*)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy}-tetrahydro-3-(4-fluorophenyl)-2*H*-pyran-4-yl)methyl]-4-ethylpiperazinone;
1-[((2*R*,3*R*,4*R*)-2-{(1*R*)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy}-tetrahydro-3-(4-fluorophenyl)-2*H*-pyran-4-yl)methyl]-4-(1-methylethyl)piperazinone;
1-[((2*R*,3*R*,4*R*)-2-{(1*R*)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy}-tetrahydro-3-(4-fluorophenyl)-2*H*-pyran-4-yl)methyl]-4-cyclohexylpiperazinone;
1-[((2*R*,3*R*,4*R*)-2-{(1*R*)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy}-tetrahydro-3-(4-fluorophenyl)-2*H*-pyran-4-yl)methyl]-4-(tetrahydropyran-4-yl)piperazinone;
1-[((2*R*,3*R*,4*R*)-2-{(1*R*)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy}-tetrahydro-3-(4-fluorophenyl)-2*H*-pyran-4-yl)methyl]-4-(1-methylpiperidin-4-yl)piperazinone;
1-[((2*R*,3*R*,4*R*)-2-{(1*R*)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy}-tetrahydro-3-(4-fluorophenyl)-2*H*-pyran-4-yl)methyl]-4-phenylpiperazinone;
1-[((2*R*,3*R*,4*R*)-2-{(1*R*)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy}-tetrahydro-3-(4-fluorophenyl)-2*H*-pyran-4-yl)methyl]-4-(pyrid-3-yl)piperazinone;
4-[((2*R*,3*R*,4*R*)-2-{(1*R*)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy}-tetrahydro-3-phenyl-2*H*-pyran-4-yl)methyl]piperazinone;
4-[((2*R*,3*R*,4*R*)-2-{(1*R*)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy}-tetrahydro-3-(4-fluorophenyl)-2*H*-pyran-4-yl)methyl]-1-methylpiperazinone;
4-[((2*R*,3*R*,4*R*)-2-{(1*R*)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy}-tetrahydro-3-(4-fluorophenyl)-2*H*-pyran-4-yl)methyl]-1-ethylpiperazinone;
4-[((2*R*,3*R*,4*R*)-2-{(1*R*)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy}-tetrahydro-3-(4-fluorophenyl)-2*H*-pyran-4-yl)methyl]-1-phenylpiperazinone;
4-[((2*R*,3*R*,4*R*)-2-{(1*R*)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy}-tetrahydro-3-(4-fluorophenyl)-2*H*-pyran-4-yl)methyl]-1-(pyrid-3-yl)piperazinone;

4-[((2*R*,3*S*,4*S*)-2-{(1*R*)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy}-tetrahydro-3-(4-fluorophenyl)-2*H*-pyran-4-yl)methyl]piperazinone;

4-[((2*R*,3*S*,4*S*)-2-{(1*R*)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy}-tetrahydro-3-(4-fluorophenyl)-2*H*-pyran-4-yl)methyl]-1-methylpiperazinone;

4-[((2*R*,3*S*,4*S*)-2-{(1*R*)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy}-tetrahydro-3-(4-fluorophenyl)-2*H*-pyran-4-yl)methyl]-1-ethylpiperazinone;

4-[((2*R*,3*R*,4*R*)-2-{(1*R*)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy}-tetrahydro-3-(3,4-difluorophenyl)-2*H*-pyran-4-yl)methyl]thiomorpholine 1,1-dioxide;

4-[((2*R*,3*R*,4*R*)-2-{(1*R*)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy}-tetrahydro-3-phenyl-2*H*-pyran-4-yl)methyl]thiomorpholine 1,1-dioxide;

1-[((2*R*,3*R*,4*R*)-2-{(1*R*)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy}-tetrahydro-3-phenyl-2*H*-pyran-4-yl)methyl]-2-pyrrolidinone;

1-[((2*R*,3*R*,4*R*)-2-{(1*R*)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy}-tetrahydro-3-phenyl-2*H*-pyran-4-yl)methyl]-2,5-pyrrolidinedione;

1-[((2*R*,3*R*,4*R*)-2-{(1*R*)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy}-tetrahydro-3-phenyl-2*H*-pyran-4-yl)methyl]-2-imidazolidinone;

1-[((2*R*,3*R*,4*R*)-2-{(1*R*)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy}-tetrahydro-3-phenyl-2*H*-pyran-4-yl)methyl]-3-methyl-2-imidazolidinone;

3-[((2*R*,3*R*,4*R*)-2-{(1*R*)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy}-tetrahydro-3-phenyl-2*H*-pyran-4-yl)methyl]-1-methyl-2,4-imidazolidinedione;

2-[((2*R*,3*R*,4*R*)-2-{(1*R*)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy}-tetrahydro-3-phenyl-2*H*-pyran-4-yl)methyl]-5-ethyl-1,2,5-thiadiazolidine 1,1-dioxide;

(5*R* or *S*)-5-((2*R*,3*R*,4*R*)-2-{(1*R*)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy}-tetrahydro-3-phenyl-2*H*-pyran-4-yl)-2,4-imidazolidinedione;

(3*R* or *S*)-3-((2*R*,3*R*,4*R*)-2-{(1*R*)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy}-tetrahydro-3-phenyl-2*H*-pyran-4-yl)-4-methylthiomorpholine 1,1-dioxide;

2-[((2*R*,3*R*,4*R*)-2-{(1*R*)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy}-tetrahydro-3-phenyl-2*H*-pyran-4-yl)methyl]isothiazolidine 1,1-dioxide;

or a pharmaceutically acceptable salt thereof.

38. (Currently amended) A pharmaceutical composition comprising the compound of ~~Claim 22~~ Claim 41 and at least one pharmaceutically acceptable carrier or excipient.

39. (Currently amended) A method for the treatment of pain or inflammation, migraine, emesis, postherpetic neuralgia, depression or anxiety, which method comprises administration to a patient in need thereof of a therapeutically effective amount of the compound of ~~Claim 22~~ Claim 41.

40. (Currently amended) A method for the prevention of pain or inflammation, migraine, emesis, postherpetic neuralgia, depression or anxiety, which method comprises administration to a patient in need thereof of a therapeutically effective amount of the compound of ~~Claim 22~~ Claim 41.

41. (New) A compound of the formula (I):



(I)

wherein:

R^1 is hydrogen, halogen, C_{1-6}alkyl, C_{1-6}alkoxy, fluoroC_{1-6}alkyl, fluoroC_{1-6}alkoxy, C_{3-7}cycloalkyl, C_{3-7}cycloalkylC_{1-4}alkyl, NO_2, CN, SR^a, SOR^a, SO_2R^a, CO_2R^a, $CONR^aR^b$, C_{2-6}alkenyl, C_{2-6}alkynyl or C_{1-4}alkyl substituted by C_{1-4}alkoxy, wherein R^a and R^b each independently represent hydrogen or C_{1-4}alkyl;

R^2 is hydrogen, halogen, C_{1-6}alkyl, fluoroC_{1-6}alkyl or C_{1-6}alkoxy substituted by C_{1-4}alkoxy;

R^3 is hydrogen, halogen or fluoroC_{1-6}alkyl;

R^4 is hydrogen, halogen, C_{1-6}alkyl, C_{1-6}alkoxy, fluoroC_{1-6}alkyl, fluoroC_{1-6}alkoxy, hydroxy, NO_2, CN, SR^a, SOR^a, SO_2R^a, CO_2R^a, $CONR^aR^b$, C_{2-6}alkenyl, C_{2-6}alkynyl or C_{1-4}alkyl substituted by C_{1-4}alkoxy;

R^5 is hydrogen, halogen, C_{1-6}alkyl, fluoroC_{1-6}alkyl or C_{1-6}alkoxy substituted by C_{1-4}alkoxy;

R^6 represents hydrogen or a C_{1-4}alkyl group which is unsubstituted or substituted by a hydroxy group;

R^7

is a cyclic group selected from the group consisting of:



X is N, CH or CH_2



X is O or CH_2
n is 1 or 2



X is O, NH, CH_2 or NR^{13}
n is 1 or 2



X is NH or CH_2



X is O, NH, CH_2 or NR^{13}
n is 1 or 2



X is O, NH, CH_2 or NR^{13}
n is 1 or 2










,

,

,

X is NR^{13} or CH_2 X is NR^{13} or CH_2


,

,

,

X is NR^{13} or CH_2 X is NR^{13}, O or SO_2


,

,

,

X is N or CH X is N or CH


and

,

X is N or CH


,

and

,

wherein cyclic group is unsubstituted or substituted at any substitutable position by one or more substituents selected from =O, halogen, hydroxy, R^{11}, R^{12}, SR^f, SO_2R^g, COR^a, CO_2R^a, $CONR^9R^{10}$,

-ZNR^9R^{10}, benzyl, C_{1-4}alkyl, hydroxyC_{1-4}alkyl, fluoroC_{1-4}alkyl, chloroC_{1-4}alkyl, C_{1-4}alkoxyC_{1-4}alkyl, C_{3-7}cycloalkyl, C_{3-7}cycloalkylC_{1-4}alkyl, C_{3-7}cycloalkoxy, C_{3-7}cycloalkoxyC_{1-4}alkyl, C_{1-4}alkoxy, fluoroC_{1-4}alkoxy, hydroxyC_{1-4}alkoxy, C_{1-4}alkoxyC_{1-4}alkoxy, aryl, arylC_{1-4}alkyl, heteroaryl, heteroarylC_{1-4}alkyl or a 5- or 6-membered ring containing in the ring one oxygen atom or N(C_{1-6}alkyl), wherein R^f is C_{1-4}alkyl or aralkyl or aryl and R^g is C_{1-4}alkyl, aryl, arylC_{1-4}alkyl or NR^9R^{10};

R^8 represents hydrogen, C_{1-6}alkyl, fluoroC_{1-6}alkyl, hydroxy, C_{1-6}alkoxy, hydroxyC_{1-6}alkyl NR^9R^{10}, $CONR^9R^{10}$ or SO_2R^g;

R^9 is hydrogen, C_{1-4}alkyl, C_{3-7}cycloalkyl, C_{3-7}cycloalkylC_{1-4}alkyl, fluoroC_{1-4}alkyl, C_{2-4}alkyl substituted by a C_{1-4}alkoxy or hydroxyl group, or R^9 is a five membered or six membered nitrogen-containing heteroaromatic ring as previously defined;

R^{10} is hydrogen or C_{1-4}alkyl, C_{3-7}cycloalkyl, C_{3-7}cycloalkylC_{1-4}alkyl, fluoroC_{1-4}alkyl or C_{2-4}alkyl substituted by a C_{1-4}alkoxy or hydroxyl group;

or R^9, R^{10} and the nitrogen atom to which they are attached form a heteroaliphatic ring of 4 to 7 ring atoms, unsubstituted or substituted by one or two groups selected from hydroxy, COR^e, CO_2R^e, C_{1-4}alkyl unsubstituted or substituted by a C_{1-4}alkoxy or hydroxyl group, or C_{1-4}alkoxy unsubstituted or substituted by a C_{1-4}alkoxy or hydroxyl group, or a five membered or six membered nitrogen-containing heteroaromatic ring as previously defined, or said heteroaliphatic ring is substituted by a spiro-fused lactone ring, and said heteroaliphatic ring optionally containing a double bond, which heteroaliphatic ring may contain an oxygen or sulphur ring atom, a group S(O) or $S(O)_2$ or a second nitrogen atom which will be part of a NH or NR^d moiety, where R^d is C_{1-4}alkyl unsubstituted or substituted by hydroxy or C_{1-4}alkoxy;

or R^9, R^{10} and the nitrogen atom to which they are attached form a non-aromatic azabicyclic ring system of 6 to 12 ring atoms;

or R^9, R^{10} and the nitrogen atom to which they are attached form a heteroaliphatic ring of 4 to 7 ring atoms to which is fused a benzene ring or a five membered or six membered nitrogen-containing heteroaromatic ring optionally containing 1, 2 or 3 additional heteroatoms selected from N, O and S;

R^{11} and R^{12} each independently represent hydrogen, hydroxy, COR^e, CO_2R^e, C_{1-4}alkyl unsubstituted or substituted by a C_{1-4}alkoxy or hydroxyl group, or C_{1-4}alkoxy unsubstituted or substituted by a C_{1-4}alkoxy or hydroxyl group;

or, when they are attached to the same carbon atom, R^{11} and R^{12} may together represent =O, $=CHCO_2R^a$, $-O(CH_2)_mO-$, $-CH_2O(CH_2)_k-$, $-CH_2OCH_2C(O)-$, $-CH_2OCH_2CH(OH)-$, $-CH_2OCH_2C(CH_3)_2-$, $-CH_2OC(CH_3)_2CH_2-$, $-C(CH_3)_2OCH_2CH_2-$, $-CH_2C(O)OCH_2-$, $-OC(O)CH_2CH_2-$, $-C(O)OCH_2CH_2-$, $-C(O)OC(CH_3)_2CH_2-$, $-C(O)OCH_2C(CH_3)_2-$, $-OCH_2(CH_2)_k-$, $-OC(CH_3)_2CH_2CH_2-$, $-OCH_2C(CH_3)_2CH_2-$, $-OCH_2CH_2C(CH_3)_2-$, $-OCH_2CH=CHCH_2-$, $-OCH_2CH(OH)CH_2CH_2-$, $-OCH_2CH_2CH(OH)CH_2-$, $-OCH_2C(O)CH_2CH_2-$, $-OCH_2CH_2C(O)CH_2-$, or a group of the formula:



or, where they are attached to adjacent carbon atoms, R^{11} and R^{12} may together represent $-OCH_2CH_2-$ or $-OCH_2CH(OH)-$, or R^{11} and R^{12} may together form a fused benzene ring;

or, R^{11} and R^{12} together form a C_{1-2}alkylene bridge across the pyrrolidine, piperidine, morpholine or piperazine ring to which they are attached;

R^{13} represents hydrogen, phenyl, benzyl, pyridyl, tetrahydropyranyl, piperidinyl, N-substituted piperidinyl (where the N-substituent is C_{1-6}alkyl), C_{1-4}alkyl, C_{3-7}cycloalkyl, C_{3-7}cycloalkylC_{1-4}alkyl, $-SO_2C_{1-4}$alkyl or C_{2-4}alkyl substituted by a C_{1-4}alkoxy or hydroxyl group;

R^{14} represents hydrogen, halogen, hydroxy, C_{1-4}alkyl, hydroxyC_{1-4}alkyl or fluoroC_{1-4}alkyl;

R^{15} and R^{16} each independently represent hydrogen, halogen, C_{1-6}alkyl, CH_2OR^c, oxo, CO_2R^a or $CONR^aR^b$ where R^a and R^b are as previously defined and R^c represents hydrogen, C_{1-6}alkyl or phenyl;

Z represents a bond, C_{1-6}alkylene or C_{3-6}cycloalkylene;

k is 1, 2 or 3;

m is 1 or 2; and

n is zero, 1 or 2;

with the proviso that when n is zero and R^8 is hydrogen, R^7 does not represent a C-linked nitrogen-containing ring of the formula:



wherein:

A represents NR^{13}, and B represents a bond, CH_2, NR^{13} or O, wherein one or both hydrogen atoms in said CH_2 moiety may be replaced with one or both of R^{11} and R^{12}, or alternatively, one of the hydrogen atoms in said CH_2 moiety together with a hydrogen atom from an adjacent carbon are replaced by a double bond; or A is O, and B is NR^{13}; and R^{11} and R^{12} together represent =O; and pharmaceutically acceptable salts thereof.